Waters Corporation

Waters Corporation (WAT) Market Cap

Waters Corporation has a market capitalization of $19.51B.

Financials based on reported quarter end 2025-12-31

Price: $327.77

β–² 8.73 (2.74%)

Market Cap: 19.51B

NYSE Β· time unavailable

CEO: Udit Batra

Sector: Healthcare

Industry: Medical - Diagnostics & Research

IPO Date: 1995-11-17

Website: https://www.waters.com

Waters Corporation (WAT) - Company Information

Market Cap: 19.51B Β· Sector: Healthcare

Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by life science, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.

Analyst Sentiment

70%
Buy

Based on 25 ratings

Analyst 1Y Forecast: $397.69

Average target (based on 4 sources)

Consensus Price Target

Low

$350

Median

$400

High

$480

Average

$403

Potential Upside: 22.8%

Price & Moving Averages

Loading chart...

πŸ“˜ Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

πŸ“˜ Waters Corporation (WAT) β€” Investment Overview

🧩 Business Model Overview

Waters Corporation is a global leader in analytical technologies, primarily serving the life sciences, materials, and food and environmental sectors. The company’s core offerings include advanced liquid chromatography, mass spectrometry, and thermal analysis systems, which are crucial tools for chemical analysis and quality control in laboratories worldwide. Waters’ client base spans pharmaceutical manufacturers, academic and government research organizations, contract research and testing labs, food and beverage companies, and chemical producers. With a reputation for innovation and high-precision instruments, Waters plays a critical role in pharmaceutical R&D, drug quality assurance, molecular biology, and environmental monitoring.

πŸ’° Revenue Model & Ecosystem

Waters derives revenue from a well-diversified set of sources anchored by the sale of high-value laboratory instrumentation and recurring streams from services, consumables, and related software. A significant portion of revenue comes from the initial sale of equipment, with follow-on sales from consumables (such as columns and reagents), proprietary and third-party software for data analysis, and long-term service contracts for maintenance and calibration. The company also provides informatics solutions that integrate into enterprise laboratory workflows, helping customers standardize and streamline complex data management across distributed labs. Waters addresses both large enterprise customers and research institutions, offering customization and scalable solutions that foster deep relationships and ongoing engagement.

🧠 Competitive Advantages

  • Brand strength: Waters is recognized globally as a pioneer in analytical laboratory technology and enjoys a reputation for reliability and scientific rigor.
  • Switching costs: Customers are typically reluctant to switch vendors given the tight integration into lab workflows, staff training needed, and the validation requirements in regulated industries such as pharma.
  • Ecosystem stickiness: Waters’ proprietary consumables and software create locked-in usage patterns, providing high visibility into recurring revenue streams as instruments are replenished and serviced over multi-year lifecycles.
  • Scale + supply chain leverage: With a global footprint and extensive field service network, Waters can deliver specialized support and maintenance more efficiently than smaller competitors, while leveraging supply chain efficiencies to maintain operational resilience.

πŸš€ Growth Drivers Ahead

Long-term growth is underpinned by global expansion in pharmaceutical R&D, increased regulatory focus on food and environmental testing, and rising investments in life science research and biopharmaceuticals. Waters is positioned to benefit from innovation cycles in mass spectrometry and chromatography, the proliferation of biologically-derived therapeutics, and the growing needs of emerging markets for sophisticated analytical instrumentation. The company continues to expand its digital portfolio, deepening laboratory informatics and automation to cater to data-intensive sciences. Collaboration with academic and commercial partners and targeted M&A activity further support Waters’ goal of cementing its role in next-generation science and discovery workflows.

⚠ Risk Factors to Monitor

Waters operates in a highly competitive environment with several well-capitalized multinational rivals offering overlapping product portfolios. Risks include technological disruption from advances in automation or alternative analytical techniques, margin pressures from pricing competition and input cost fluctuations, and challenges defending intellectual property. Regulatory headwinds in pharmaceutical and chemical testing, as well as shifting capital expenditure cycles among major customers, may affect demand visibility. Rapid innovation cycles and potential commoditization in consumables or informatics also represent ongoing strategic risks.

πŸ“Š Valuation Perspective

Waters is typically valued by the market at a premium relative to many industrial instrumentation peers, reflecting the defensiveness of its recurring revenue from consumables and services, as well as its entrenched position within regulated, high-growth life science markets. This valuation often embodies expectations for consistent cash generation and the perceived resilience of laboratory spending. Comparisons are frequently drawn against other leading analytical instrument vendors, with a focus on recurring revenue mix, end-market exposure, and innovation track record.

πŸ” Investment Takeaway

The investment case for Waters Corporation rests on its durable position in science-driven end markets, robust recurring revenue model, and reputation for technological leadership. Bulls highlight Waters' sticky customer relationships, ability to innovate in fast-evolving fields like biological therapeutics and laboratory automation, and its agility in addressing regulatory and scientific trends. Bears point to intensifying competition, potential for disruptive technology, and the cyclical sensitivity of customer capital spending. Investors should weigh Waters’ entrenched competitive advantages and long-term growth prospects against market risks and the premium typically afforded to its shares.


⚠ AI-generated research summary β€” not financial advice. Validate using official filings & independent analysis.

Waters delivered a strong Q4 and FY25, finishing at the high end of guidance with robust recurring revenue and continued LC-MS strength. The acquisition of BD’s Biosciences and Diagnostic Solutions is positioned as transformative, with clear cost and revenue synergy plans and a new divisional structure to drive execution. Management guides to mid-single- to high-single-digit organic growth for 2026 in the legacy business and sees multi-year tailwinds from instrument replacement, innovation, and five idiosyncratic growth drivers, while noting near-term headwinds at the acquired units and a temporary revenue impact from the shift to subscription informatics.

Growth

  • Q4 reported sales +7% (+6% cc); adjusted EPS up low double digits to $4.53 (GAAP $3.77)
  • Q4 recurring revenue +9% (chemistry led); instruments +3% with high single-digit LC-MS growth; TA Instruments declined
  • FY25 sales +7% (reported and cc); recurring revenue +8% (chemistry +12%); instruments +5% with LC-MS high single-digit or better each quarter
  • China FY25 revenue +9%; Pharma +9% (Americas/Europe high single-digit; Asia low double-digit); Industrial +6%; Academic & Government -1%
  • Alliance iS HPLC sales >2x; Xevo TQ Absolute mass spec >+30%; MaxPeak Premier chemistry >+35%
  • Idiosyncratic drivers added >300 bps to FY25 growth: GLP-1s ~+100 bps; PFAS ~+80 bps; India generics ex-GLP-1 low-teens growth (~$40M, ~+130 bps)

Business Development

  • Closed acquisition of BD’s Biosciences and Diagnostic Solutions businesses
  • Launched/expanded products: Xevo CDMS; Absolute XR; SEC columns for viral vectors; slalom chromatography for large oligos; affinity-based separations
  • Expanded LC-MS IVD menu: +12 endocrinology analytes and +4 therapeutic drug monitoring analytes over two years
  • Transitioning Empower to subscription model; early wins with multiple large pharma customers
  • Expanded idiosyncratic growth drivers to five: GLP-1s, PFAS, India generics, biologics, informatics

Financials

  • Q4 results landed at high end of guidance for sales and adjusted EPS
  • Q4: reported sales +7% (+6% cc); adjusted EPS $4.53; GAAP EPS $3.77
  • FY25: sales +7% (reported and cc); adjusted EPS $13.13 (+11%); GAAP EPS $10.76
  • Subscription transition for Empower reduced Q4 overall instrument growth by a low single-digit percentage
  • Service plan attachment reached 54% (+~400 bps YoY); e-commerce ~45% of consumables revenue
  • Contract organizations now 27% of pharma sales (up from 15% five years ago)

Capital & Funding

  • Integration synergy targets: 2026 cost synergies ~+$55M adjusted EBIT; 2026 revenue synergies ~+$50M revenue and ~+$25M adjusted EBIT
  • Cost synergy levers: restructuring, procurement savings, and network optimization beginning in 2026
  • Baseline synergy plan <5% of combined cost base, with potential to exceed

Operations & Strategy

  • New operating structure with four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, Waters Material Sciences
  • Focus areas to lift execution at acquired businesses: instrument replacement, e-commerce adoption, service attachment, pricing discipline via deal desk
  • Instrument replacement cycle strengthening: instrument growth tracking ~2.5% CAGR vs 2019 (up ~100 bps), trending toward ~5% long-term rate
  • Revenue synergy levers: +~100 incremental instrument replacements/year among ~22,000 Flow/BACTEC units to drive ~$20M by year 5; increase service attachment ~1 ppt/year; increase e-commerce adoption ~4 ppts/year
  • Informatics shift to subscriptions: revenue recognized ratably; ~18-month cumulative revenue breakeven; targeted growth from ~$300M to ~$500M by 2030
  • LC-MS into diagnostics to benefit from acquired commercial scale, channel access, and automation

Market & Outlook

  • 2026 organic cc revenue growth guidance (legacy Waters businesses): 5.5%–7%
  • Expect continued momentum from instrument replacement and new product innovation
  • Five idiosyncratic drivers expected to contribute >200 bps of annual revenue growth accretion (stand-alone) through 2030
  • Informatics subscription transition expected to become a positive structural driver beginning in 2027
  • Potential upside from FDA draft biosimilars guidance favoring comparative analytical assessments
  • Acquired BD businesses saw near-term weakness: China diagnostics consumption reductions; U.S. government shutdown delaying export approvals; milder flu season impacting point-of-care testing

Risks Or Headwinds

  • TA Instruments declined on cautious spending in the U.S. and Europe
  • Informatics subscription transition temporarily depresses instrument revenue growth and shifts revenue timing
  • China demand weakness in diagnostics; U.S. government shutdown delays; milder flu season reduced point-of-care volumes in acquired business
  • Integration execution and synergy realization risks
  • Regulatory and reimbursement uncertainties in diagnostics; evolving PFAS regulatory landscape

Sentiment: MIXED

Note: This summary was synthesized by AI from the WAT Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Fundamentals Overview

Loading fundamentals overview...

πŸ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"The company reported revenue of $932.36 million and a net income of $225.21 million for the latest quarter, resulting in an EPS of $3.78. The firm's net margin stands at approximately 24.15%, indicating strong profitability. The free cash flow for the quarter was $161.87 million. Year-over-year growth remains respectable, contributing to positive momentum. Growth has been steady, but precise YOY figures require historical context. Profitability is robust, supported by healthy margins and efficient operations. The balance sheet reveals substantial financial health with negative net debt of $587.83 million, reflecting a solid cash position that surpasses its debt. Cash flow quality is strong, evidenced by positive operating cash flows and prudent capital expenditure. The company has not paid dividends recently and engages minimally in stock repurchases or issues. Shareholder returns rely predominantly on stock price appreciation. The consensus price target suggests a mild upside from the current valuation. Overall, the firm demonstrates strong financial fundamentals, capable cash generation, and disciplined capital management."

Revenue Growth

Positive

Revenue growth is stable, though precise historic growth metrics are needed to assess trends.

Profitability

Strong

The company exhibits excellent profitability with a solid net margin above 24% and a strong EPS.

Cash Flow Quality

Good

Strong free cash flow supported by high operating cash flow and manageable capex levels.

Leverage & Balance Sheet

Strong

Negative net debt underscores financial resilience, with ample liquidity.

Shareholder Returns

Neutral

Returns focus on appreciation, with minimal dividends or buybacks; past dividend was a one-time occurrence.

Analyst Sentiment & Valuation

Positive

The consensus target indicates moderate upside; valuations are considered fair.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Loading financial data and tables...
πŸ“

SEC Filings (WAT)

Β© 2026 Stock Market Info β€” Waters Corporation (WAT) Financial Profile